Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1

Conditions

Melanoma 3Neoplasms 2HIV Infections 2Carcinoma, Hepatocellular 2Acquired Immunodeficiency Syndrome 2Stomach Ulcer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Muscle Neoplasms 1Hepatitis B 1Duodenal Ulcer 1Adenoviridae Infections 1AIDS-Related Complex 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Tumor Necrosis Factor-alpha × Clear all
NCT06222801 2024-06-10

The 1st Tumor CytokinoTherapy Database (TCTD-1)

OncoCareClinic 308 Ltd

Recruiting
5,000 enrolled
Tumor-Agnostic

Neoplasms

NCT00019968 2023-10-31

Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
Sarcoma

Neoplasms, Sarcoma, Muscle Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡